Raven Biotech begins phase I/IIa gastrointestinal cancers trial
The phase I/IIa, open-label, dose-escalation clinical trial is being conducted at three leading oncology centers in the US. It will include approximately 30 patients with colon, stomach or pancreatic cancer, or other target antigen positive adenocarcinomas, including breast, lung and prostate. The trial is designed to measure the safety and tolerability of RAV12. Raven expects to conclude the trial by the second half of 2005. "We are hopeful that RAV12 will become an option for patients in the treatment of advanced stage adenocarcinoma," said Dr Howard Burris, principal investigator from the Sarah Cannon Research Institute, Nashville, Tennessee. "We are pleased to be participating in the clinical trial and have dosed the first patients."